Part 5/8:
Kristine Harjes and Todd Campbell, financial analysts closely following the situation, pointed out that the trial conducted by Sarepta involved only 12 patients and used a "historical control group." This means there was no conventional comparison between a treated group and a control group, raising questions about the validity of the results. An internal FDA report voiced concerns regarding the small sample size, stating that the clinical outcomes observed in the trial appeared to align with the expected natural progression of DMD.